Multiple Myeloma Research Foundation Awards $7 Million to Accelerate Precision Immunotherapies for Myeloma Patients
As part of its $15 million Immunotherapy Initiative, the…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Xgeva Gains Europe’s Approval for Preventing Bone Lesions in Multiple Myeloma
The European Commission has extended Xgeva‘s (denosumab) approval…
Revlimid, Dexamethasone Combo Shows Benefits for Multiple Myeloma in Real-world Study
The combination of Revlimid (lenalidomide) and dexamethasone for the treatment…
Bluebird Bio and Celgene Partner to Advance bb2121, Potential Multiple Myeloma CAR T-cell Therapy
The investigational therapy bb2121, a possible treatment for…
ACCoRd Trial to Test Ninlaro Treatment for ASCT-Relapsed Multiple Myeloma
A new Phase 3 clinical trial called ACCoRd is…
AbbVie, IMF Team Up to Study Gene Mutation in Myeloma Outcomes
AbbVie and the International Myeloma Foundation are collaborating…
